Skip to main content
Skip to main content
ALCN logo

Atlantic Central Enterprise Ltd. (ALCN)

$0.00 +$0.00 (+0.00%) |CouncilHOLD · 40 · C
Signals are mixed — the Council read leans HOLD (40/100) while the AI fundamental score is 57/100 (grade B); the two lenses disagree, so weigh the breakdown below. Strongest single signal: Seth Klarman bearish.
MCap: 400| Vol: 68.8K| 52-wk range: $0.00 – $0.00
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Atlantic Central Enterprise Ltd. (ALCN) trades at $0.00 with AI Score 57/100 (Grade B). Atlantic Central Enterprise Ltd. , through its subsidiary Vista Technologies, Inc. Market cap: $400, Sector: Industrials.

Price live · AI analysis from Mar 17, 2026
Atlantic Central Enterprise Ltd., through its subsidiary Vista Technologies, Inc., provides photorefractive keratectomy and other laser vision correction facilities and services. The company primarily operates in the United States and western Europe.

Analyst Coverage for ALCN: ALCN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALCN against Industrials peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.

Council Score · Weighted Average of 3 Disciplines
HOLD 40/100 · C

ALCN: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Izzy Englander
Neutral
Seth Klarman
Bearish
Moon AI
Neutral
Council Score · 8 perspectives · See tabs for details →

Atlantic Central Enterprise Ltd. (ALCN) Industrial Operations Profile

CEOPatrick J. Rooney
HeadquartersHamilton, BM
IPO Year2023

Atlantic Central Enterprise Ltd., operating through Vista Technologies, provides laser vision correction services, primarily in the US and Western Europe. As an OTC-listed company in the specialty business services sector, it faces unique challenges related to liquidity and regulatory oversight, while serving a niche market within the healthcare industry.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 17, 2026

What Is the Investment Thesis for ALCN?

Atlantic Central Enterprise Ltd. presents a speculative investment opportunity due to its presence in the niche market of laser vision correction services. With a gross margin of 100.0%, the company demonstrates potential profitability, but its market capitalization of 400 raises concerns about its financial stability and growth prospects. Key value drivers include the increasing demand for vision correction procedures and the company's ability to maintain its high gross margin. However, the negative beta of -9.94 indicates an inverse correlation with the market, suggesting it may not perform well during economic expansions. The company's OTC listing introduces additional risks related to liquidity and regulatory oversight. Investors should carefully weigh the potential rewards against the significant risks before considering an investment in ALCN.

Based on FMP financials and quantitative analysis

ALCN Key Highlights

  • Gross Margin of 100.0% indicates strong potential profitability in its service offerings.
  • Market Cap of 400 signals potential financial instability and limited investor confidence.
  • Beta of -9.94 suggests an inverse correlation with the market, potentially underperforming during economic growth.
  • Operations primarily in the United States and Western Europe provide access to developed healthcare markets.
  • Focus on photorefractive keratectomy and laser vision correction services caters to a specific niche within the healthcare industry.

Who Are ALCN's Competitors?

ALCN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
FTBGF Bidstack Group Plc $0.03 +20.00% $29.04M 63
BUUU BUUU Group Limited provides meeting, incentive, conference, and exhibition solutions, including event management and stage production services. The company $21.35 -2.06% $249.69M 63
ZGM Zenta Group Company Limited $1.99 +11.80% $23.50M 60
INPOF InPost S.A. $17.47 +0.00% $8.73B 60
ULS UL Solutions Inc. $90.70 -6.49% $18.25B 57
PRSU Pursuit Attractions and Hospitality, Inc. $54.80 -1.07% $1.50B 58
NTIP Network-1 Technologies, Inc. $1.47 -1.34% $33.61M 58
FA First Advantage Corporation $20.15 -1.85% $3.46B 58

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALCN's Key Strengths?

  • Specialized services in laser vision correction.
  • High gross margin of 100.0%.
  • Operations in developed markets (US and Western Europe).
  • Established subsidiary, Vista Technologies, Inc.

What Are ALCN's Weaknesses?

  • Market capitalization of 400 indicates financial instability.
  • Negative beta of -9.94 suggests poor performance during economic growth.
  • OTC listing introduces liquidity and regulatory risks.
  • Limited information available about the company's current operations.

What Could Drive ALCN Stock Higher?

  • Potential partnerships with healthcare providers to expand service reach (Timeline: 1-2 years).
  • Development of new laser vision correction technologies to enhance service offerings (Timeline: 2-4 years).
  • Expansion into emerging markets with growing demand for vision correction (Timeline: 3-5 years).

What Are the Key Risks for ALCN?

  • Limited liquidity due to OTC Other status may hinder trading activities.
  • Lack of financial transparency and disclosure could obscure financial health.
  • Competition from established vision care providers may erode market share.
  • Changes in healthcare regulations and reimbursement policies could impact revenue.
  • Negative beta suggests potential underperformance during economic growth.

What Are the Growth Opportunities for ALCN?

  • Expansion into Emerging Markets: Atlantic Central Enterprise Ltd. could explore opportunities in emerging markets where the demand for laser vision correction is growing. These markets often have less competition and a growing middle class with increasing disposable income for elective medical procedures. A successful expansion would require adapting its services to local regulations and cultural preferences. The timeline for realizing significant revenue from emerging markets is estimated at 3-5 years, with the potential to increase overall revenue by 15-20%.
  • Development of New Laser Vision Correction Technologies: Investing in research and development to create new and improved laser vision correction technologies could provide a competitive edge. This includes exploring advancements in femtosecond lasers, wavefront-guided treatments, and other innovative approaches. Successful development and commercialization of new technologies could attract more patients and increase market share. The timeline for developing and launching new technologies is estimated at 2-4 years, with the potential to increase revenue by 10-15%.
  • Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, clinics, and other healthcare providers can expand the company's reach and access to patients. These partnerships can involve offering on-site laser vision correction services or providing referral programs. Collaborating with established healthcare providers can enhance the company's credibility and attract more customers. The timeline for establishing strategic partnerships is estimated at 1-2 years, with the potential to increase patient volume by 5-10%.
  • Offering Subscription-Based Vision Care Packages: Introducing subscription-based vision care packages that include laser vision correction, follow-up care, and other related services can generate recurring revenue and enhance customer loyalty. These packages can be tailored to different patient needs and budgets, providing a flexible and convenient way to access vision care services. The timeline for developing and launching subscription-based packages is estimated at 6-12 months, with the potential to increase customer retention by 20-25%.
  • Telemedicine and Remote Consultation Services: Leveraging telemedicine and remote consultation services can expand the company's reach to patients in remote areas or those who prefer virtual consultations. This includes offering online consultations, virtual eye exams, and remote monitoring of patients' vision. Telemedicine can improve patient access to care and reduce the need for in-person visits. The timeline for implementing telemedicine services is estimated at 3-6 months, with the potential to increase patient reach by 10-15%.

What Opportunities Does ALCN Have?

  • Expansion into emerging markets.
  • Development of new laser vision correction technologies.
  • Strategic partnerships with healthcare providers.
  • Offering subscription-based vision care packages.

What Threats Does ALCN Face?

  • Competition from established vision care providers.
  • Technological advancements rendering current services obsolete.
  • Changes in healthcare regulations and reimbursement policies.
  • Economic downturns affecting demand for elective procedures.

What Are ALCN's Competitive Advantages?

  • Specialized expertise in laser vision correction.
  • Established presence in the US and Western European markets.
  • Proprietary technology or techniques (if applicable).
  • Strong relationships with healthcare providers (if applicable).

What Does ALCN Do?

Atlantic Central Enterprise Ltd., formerly known as Bamburgh Limited, was incorporated in 1996 and is headquartered in Hamilton, Bermuda. The company operates through its subsidiary, Vista Technologies, Inc., focusing on providing photorefractive keratectomy and other laser vision correction facilities and services. These services are primarily offered to the healthcare industry, targeting patients seeking vision correction solutions. The company's operational footprint is mainly concentrated in the United States and western Europe, reflecting its strategic focus on developed markets with established healthcare infrastructures. Since its inception, Atlantic Central Enterprise Ltd. has aimed to carve a niche in the specialty business services sector by offering specialized healthcare services. The company's evolution reflects a commitment to leveraging technological advancements in laser vision correction to meet the demands of a growing market. While the company has maintained a consistent focus on its core business, its ability to navigate the competitive landscape and adapt to changing market dynamics remains crucial for sustained growth and profitability. The company's history includes a name change in 1996, signaling a strategic shift or rebranding effort to align with its business objectives.

What Products and Services Does ALCN Offer?

  • Provides photorefractive keratectomy (PRK) services.
  • Offers other laser vision correction procedures.
  • Operates through its subsidiary, Vista Technologies, Inc.
  • Serves the healthcare industry.
  • Focuses on vision correction solutions.
  • Operates primarily in the United States and western Europe.

How Does ALCN Make Money?

  • Generates revenue by providing laser vision correction services.
  • Offers these services to patients through healthcare facilities.
  • Operates primarily in the US and Western Europe.
  • Focuses on photorefractive keratectomy and related procedures.

What Industry Does ALCN Operate In?

Atlantic Central Enterprise Ltd. operates within the specialty business services sector, catering specifically to the healthcare industry with laser vision correction services. The market for laser vision correction is influenced by technological advancements, patient demographics, and regulatory standards. The competitive landscape includes companies offering similar services, as well as broader vision care providers. The industry is subject to ongoing advancements in laser technology and surgical techniques, requiring companies to invest in research and development to remain competitive. The company's success depends on its ability to differentiate its services, maintain high-quality standards, and effectively market its offerings to potential customers.

Who Are ALCN's Key Customers?

  • Individuals seeking vision correction.
  • Healthcare facilities offering vision correction services.
  • Patients in the United States and western Europe.
  • Individuals with refractive errors such as myopia, hyperopia, and astigmatism.
AI Confidence: 67% Updated: Mar 17, 2026

Company Profile

Atlantic Central Enterprise Ltd. operates in the Specialty Business Services industry within the Industrials sector. It is headquartered in Hamilton, BM. The company is led by CEO Patrick J. Rooney. ALCN has traded publicly since 2023.

Atlantic Central Enterprise Ltd. (ALCN) Valuation Context

Valued at 400, ALCN is classified as a micro-cap stock. Relative to its peer group, ALCN's quantitative score of 57/100 is roughly in line with the peer average of 61/100.

ROE 0%Key Financial Metrics

Return on equity for Atlantic Central Enterprise Ltd. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. ALCN trades at a trailing price-to-earnings ratio of 0.00, below the Industrials sector average of ~30x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.84 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

ALCN Financials

Bull Case vs Bear Case

Bull Case

  • Specialized services in laser vision correction.
  • High gross margin of 100.0%.
  • Operations in developed markets (US and Western Europe).
  • Established subsidiary, Vista Technologies, Inc.

Bear Case

  • Market capitalization of 400 indicates financial instability.
  • Negative beta of -9.94 suggests poor performance during economic growth.
  • OTC listing introduces liquidity and regulatory risks.
  • Limited information available about the company's current operations.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026

ALCN Latest News

No recent news available for ALCN.

ALCN Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALCN.

Price Targets

Wall Street price target analysis for ALCN.

ALCN MoonshotScore

57/100

What does this score mean?

The MoonshotScore rates ALCN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Patrick J. Rooney

CEO

Patrick J. Rooney is the CEO of Atlantic Central Enterprise Ltd. Information regarding his detailed career history, education, and previous roles is not available. His leadership is crucial for guiding the company's strategic direction and navigating the challenges of the specialty business services sector. Further information is needed to assess his qualifications and experience in the healthcare industry.

Track Record: Due to limited information, Patrick J. Rooney's specific achievements, strategic decisions, and company milestones under his leadership cannot be determined. Assessing his impact on Atlantic Central Enterprise Ltd.'s performance requires access to more detailed information about his tenure and contributions to the company's growth and development.

ALCN OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, may not meet minimum financial standards, and are subject to higher risks. Investing in OTC Other securities carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in an OTC Other company.

Shell Risk: This security has been flagged for shell risk by OTC Markets.
  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Liquidity for ALCN is likely very limited given its OTC Other status and 400 market cap. Expect wide bid-ask spreads and difficulty executing large trades without significantly impacting the price. This illiquidity poses a significant risk for investors, as it may be challenging to exit positions quickly or at a desired price.
OTC Risk Factors:
  • Limited liquidity due to OTC Other status.
  • Lack of financial transparency and disclosure.
  • Potential for fraud or manipulation.
  • Higher risk of delisting or suspension of trading.
  • Limited regulatory oversight and investor protection.
Due Diligence Checklist:
  • Verify the company's legal status and registration.
  • Obtain and review any available financial statements.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Understand the risks associated with investing in OTC Other securities.
  • Consult with a financial advisor before making any investment decisions.
Legitimacy Signals:
  • Company has been incorporated since 1996.
  • Subsidiary, Vista Technologies, Inc., focuses on a specific healthcare service.
  • Operations are primarily in the United States and western Europe.

ALCN Industrials Stock FAQ

What does Atlantic Central Enterprise Ltd. do?

Atlantic Central Enterprise Ltd., through its subsidiary Vista Technologies, Inc., specializes in providing photorefractive keratectomy and other laser vision correction services to the healthcare industry. Operating mainly in the United States and western Europe, the company focuses on offering vision correction solutions. Its business model centers around delivering these specialized services to patients seeking alternatives to traditional vision aids. The company's success depends on its ability to maintain high-quality standards, adapt to technological advancements, and effectively market its services to potential customers within the competitive vision care market.

What do analysts say about ALCN stock?

As of 2026-03-17, there is no available analyst coverage or consensus for Atlantic Central Enterprise Ltd. (ALCN). This lack of coverage is likely due to its OTC listing and small market capitalization. Key valuation metrics are difficult to assess due to the limited financial information available. Investors should exercise caution and conduct thorough due diligence before considering an investment in ALCN, given the absence of independent analyst opinions and the inherent risks associated with OTC-listed companies.

What are the main risks for ALCN?

The main risks for Atlantic Central Enterprise Ltd. include its OTC Other listing, which implies limited liquidity and regulatory oversight. The company's small market capitalization of 400 and negative beta of -9.94 further raise concerns about its financial stability and market performance. Competition from established vision care providers and potential changes in healthcare regulations also pose significant threats. The lack of financial transparency and disclosure adds to the overall risk profile, making it difficult for investors to assess the company's true value and potential for growth.

What are the key factors to evaluate for ALCN?

Atlantic Central Enterprise Ltd. (ALCN) holds an AI score of 57/100 (moderate). Not financial advice.

How frequently does ALCN data refresh on this page?

ALCN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven ALCN's recent stock price performance?

Atlantic Central Enterprise Ltd. (ALCN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized services in laser vision correction. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ALCN overvalued or undervalued right now?

Valuing Atlantic Central Enterprise Ltd. (ALCN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying ALCN?

Before investing in Atlantic Central Enterprise Ltd. (ALCN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available for this company. OTC listed with shell risk detected.
  • AI analysis pending.
Data Sources

Popular Stocks